^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

TheraSphere (yttrium 90 microspheres)

Associations
Company:
Boston Scientific
Drug class:
Beta radiation emitter
Related drugs:
Associations
2d
INDIGO: TheraSphere Japan Pre-Market Study (clinicaltrials.gov)
P=N/A, N=51, Recruiting, Boston Scientific Corporation
New trial
|
TheraSphere (yttrium 90 microspheres)
5d
FRONTIER: A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM (clinicaltrials.gov)
P1, N=36, Recruiting, Boston Scientific Corporation | Trial completion date: Jun 2026 --> Jan 2027 | Trial primary completion date: Mar 2026 --> Jul 2026
Trial completion date • Trial primary completion date • First-in-human
|
TheraSphere (yttrium 90 microspheres)
10d
Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma (clinicaltrials.gov)
P=N/A, N=64, Not yet recruiting, University of California, San Francisco | Trial completion date: May 2028 --> Dec 2028 | Initiation date: Nov 2025 --> May 2026 | Trial primary completion date: May 2028 --> Dec 2028
Trial completion date • Trial initiation date • Trial primary completion date
|
TheraSphere (yttrium 90 microspheres)
13d
Enrollment closed
|
Avastin (bevacizumab) • Imfinzi (durvalumab) • TheraSphere (yttrium 90 microspheres)
19d
Trial completion
|
TheraSphere (yttrium 90 microspheres)
3ms
Enrollment change
|
Avastin (bevacizumab) • Imfinzi (durvalumab) • TheraSphere (yttrium 90 microspheres)
4ms
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk (clinicaltrials.gov)
P2, N=84, Suspended, Northwestern University | Trial primary completion date: Jul 2025 --> Jul 2026
Trial primary completion date
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • TheraSphere (yttrium 90 microspheres)
5ms
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)
P2, N=30, Recruiting, University of Miami | Not yet recruiting --> Recruiting | Trial completion date: Aug 2030 --> Nov 2030 | Initiation date: Aug 2025 --> Nov 2025 | Trial primary completion date: Aug 2030 --> Nov 2030
Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
|
Stivarga (regorafenib) • TheraSphere (yttrium 90 microspheres)
5ms
ROWAN: TheraSphere With Durvalumab and Tremelimumab for HCC (clinicaltrials.gov)
P2, N=100, Active, not recruiting, Boston Scientific Corporation | Recruiting --> Active, not recruiting
Enrollment closed
|
Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • TheraSphere (yttrium 90 microspheres)
6ms
Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma (clinicaltrials.gov)
P=N/A, N=64, Not yet recruiting, University of California, San Francisco
New trial
|
TheraSphere (yttrium 90 microspheres)
9ms
FRONTIER: A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM (clinicaltrials.gov)
P1, N=36, Recruiting, Boston Scientific Corporation | Active, not recruiting --> Recruiting | N=12 --> 36 | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Mar 2026
Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
|
TheraSphere (yttrium 90 microspheres)
10ms
New P2 trial
|
Stivarga (regorafenib) • TheraSphere (yttrium 90 microspheres)